Table 7.

New evidence on the OIR/AWR recommendation provided at a review of the guidance

Original	Review	Additional evidence provided for the OIR/AWR indication?	Summary of change to OIR/AWR guidance
TA5	TA69	New evidence available (requested pilot implementation data became available)	OIR removed
			Technology recommended
TA6	TA30	No additional evidence presented	OIR amended
			OIR recommendation for a more restricted indication
TA16	TA89	Updated RCT data and new non-RCT evidence	OIR unchanged
			(Some amendments to types of evidence required)
TA17	TA105	New evidence (RCTs) available	OIR removed
			Technology recommended
TA30	CG81	New evidence (RCT and registry data) available	OIR removed
			CG81 did not include the OIR indication in the scope of the guideline
TA33	TA93	No new RCTs, but updated adverse effect data	OIR unchanged
TA36	TA130 (only in ACD)	New RCT and registry data available	AWR removed
			Technologies recommended. A new OIR recommendation for another use of the drugs was in the ACD, but this was removed in the FAD
TA37	TA137	No new evidence presented	OIR removed
			Technology recommended
TA51	TA97	New evidence (RCT and non-RCT) available	OIR amended
			OIR targeted to specific packages rather than CCBT as a class
TA72	CG79	New evidence (RCTs) available	OIR unchanged

For further information about the TAs and CGs listed in this table, visit the NICE website: http://www.nice.org.uk/

ACD Appraisal Consultation Document, AWR approval with research, CCBT computerized cognitive behavioural therapy, CG clinical guideline, FAD Final Appraisal Determination, OIR only in research, RCT randomized controlled trial, TA technology appraisal